(Press-News.org) ROCHESTER, Minn. -- Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, according to the results of a Mayo Clinic study published in the Journal of the National Cancer Institute.
For years, controversy has surrounded the CYP2D6 gene test for breast cancer. Women with certain inherited genetic deficiencies in the CYP2D6 gene metabolize tamoxifen less efficiently, and thus have lower levels of tamoxifen's active cancer-fighting metabolite endoxifen. Numerous studies have shown that these women gain less benefit from tamoxifen therapy and have higher rates of recurrence.
However, two large clinical trials found no link between the CYP2D6 genotype and tamoxifen effectiveness, prompting recommendations against testing. In the new Mayo Clinic study, researchers found that previous studies, which used tumor tissue instead of healthy tissue to determine the CYP2D6 genotype, were prone to error. The study found that up to 45 percent of breast tumors exhibit genetic alterations affecting the CYP2D6 gene. Thus, the use of tumor tissue to obtain DNA leads to a distortion of the patient's true or inherited CYP2D6 genotype.
"The potential benefit of CYP2D6 testing is obvious but has been difficult to establish. One major reason appears to be the lack of analytical validity," says Matthew Goetz, M.D., an oncologist at the Mayo Clinic Cancer Center and senior author of the study. "We found that if you use tumor tissue to determine the CYP2D6 genotype a patient was born with, you are going to get it wrong a substantial portion of the time."
CYP2D6, which stands for Cytochrome P450 2D6, is one of the most important enzymes involved in drug metabolism. It is responsible for the breakdown of nearly a quarter of all medicines prescribed. The CYP2D6 gene is highly variable. That variability is the main genetic factor affecting how the liver metabolizes tamoxifen, and the blood levels of the important metabolite endoxifen.
"It is sobering to consider that a decade of work by the oncology community has not produced a clear resolution of the value of CYP2D6 genotype for predicting tamoxifen efficacy," says James Ingle, M.D., an oncologist at Mayo Clinic Cancer Center and co-author of the study. "The potential impact of the delay in resolving this issue is quite large in that during this time over half a million women worldwide would have been expected to be poor metabolizers, and, if the relationship between CYP2D6 genotype and tamoxifen efficacy is correct, these women would have been given less than optimal adjuvant therapy had they received tamoxifen."
Most individuals carry two copies or alleles of the CYP2D6 gene, one inherited from each parent. However, Dr. Goetz and his colleagues identified that up to 45 percent of breast tumors lose one of these "parental" CYP2D6 alleles, a phenomenon known as loss of heterozygosity. Use of tumor DNA to derive CYP2D6 genotype resulted in a distortion of the inherited CYP2D6 genotype and the inability to predict the concentrations of endoxifen.
To explore whether use of tumor tissue to obtain DNA could result in CYP2D6 genotyping errors, the researchers first looked for loss of heterozygosity at the CYP2D6 locus in genomic tumor data from two large breast cancer datasets, the Cancer Genome Atlas and Foundation Medicine. They found loss of heterozygosity in over 40 percent of the breast tumors analyzed. These findings suggested that genotyping techniques using DNA extracted from tumor samples could misclassify a patient's CYP2D6 genotype.
Next, the researchers sought to directly compare CYP2D6 genotypes derived from patients who provided normal and tumor tissue. Using samples from patients enrolled in the NCCTG 89-30-52 tamoxifen trial, the researchers showed that there was perfect agreement between CYP2D6 genotypes derived from non-malignant tissue and those derived from cheek swabs. In contrast, 20 percent of the CYP2D6 genotypes were misclassified when tumor tissue was used.
The researchers say their results should prompt a careful reassessment of the data necessary to inform patients and clinicians properly about the value of CYP2D6 testing. "We believe that previously published studies should be re-examined in the context of potential genotyping errors, specifically in those studies that utilized tumor tissue as the primary DNA source," says Mark Ratain, M.D., professor of medicine at the University of Chicago and co-author of the study. "Given the difficulties of using tumor tissue for genotyping, we also recommend that blood for DNA be routinely obtained in large oncology clinical trials."
INFORMATION:
Co-authors from Mayo Clinic include Vera Suman, Ph.D., Stephanie Safgren, Mary Kuffel, Matthew Ames, Ph.D., and Krishna Kalari, Ph.D.
The study was funded by the National Institutes of Health, the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE), and the Breast Cancer Research Foundation.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 1-855-776-0015 (toll-free).
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org.
Yeast cells can sometimes reverse the protein misfolding and clumping associated with diseases such as Alzheimer's, according to new research from the University of Arizona.
The new finding contradicts the idea that once prion proteins have changed into the shape that aggregates, the change is irreversible.
"It's believed that when these aggregates arise that cells cannot get rid of them," said Tricia Serio, UA professor and head of the department of molecular and cellular biology. "We've shown that's not the case. Cells can clear themselves of these aggregates."
Prions ...
COLUMBUS, Ohio - Thinking you're good at math and actually being good at it are not the same thing, new research has found.
About one in five people who say they are bad at math in fact score in the top half of those taking an objective math test. But one-third of people who say they are good at math actually score in the bottom half.
"Some people mis-categorize themselves. They really don't know how good they are when faced with a traditional math test," said Ellen Peters, co-author of the study and professor of psychology at The Ohio State University.
The results ...
GAINESVILLE, Fla. --- Mathematical models predicted it, and now a University of Florida study confirms it: Immunizing school-aged children from flu can protect other segments of the population, as well.
When half of 5- to 17-year-old children in Alachua County were vaccinated through a school-based program, the entire age group's flu rates decreased by 79 percent. Strikingly, the rate of influenza-like illness among 0-4 year olds went down 89 percent, despite the fact that this group was not included in the school-based vaccinations. Among all non-school-aged residents, ...
Supplemental ultrasound screening for all U.S. women with dense breasts would substantially increase healthcare costs with little improvement in overall health, according to senior author Anna Tosteson, ScD, at Dartmouth Hitchcock's Norris Cotton Cancer Center and The Dartmouth Institute for Health Policy and Clinical Practice.
In a study released Monday in the Annals of Internal Medicine, Tosteson and colleagues, including lead author Brian Sprague, MD, provide evidence on the benefits and harms of adding ultrasound to breast cancer screening for women who have had a ...
CHAMPAIGN, Ill. -- When a large protein unfolds in transit through a cell, it slows down and can get stuck in traffic. Using a specialized microscope -- a sort of cellular traffic camera -- University of Illinois chemists now can watch the way the unfolded protein diffuses.
Studying the relationship between protein folding and transport could provide great insight into protein-misfolding diseases such as Alzheimer's and Huntington's. Chemistry professor Martin Gruebele and graduate students Minghao Guo and Hannah Gelman published their findings in the journal PLOS ONE.
"We're ...
Irvine, Calif., Dec. 9, 2014 -- A learning technique that maximizes the brain's ability to make and store memories may help overcome cognitive issues seen in fragile X syndrome, a leading form of intellectual disability, according to UC Irvine neurobiologists.
Christine Gall, Gary Lynch and colleagues found that fragile X model mice trained in three short, repetitious episodes spaced one hour apart performed as well on memory tests as normal mice. These same fragile X rodents performed poorly on memory tests when trained in a single, prolonged session - which is a standard ...
A new study links ADHD and conduct disorder in young adolescents with increased alcohol and tobacco use. The Cincinnati Children's Hospital Medical Center study is among the first to assess such an association in this age group.
Conduct disorder is a behavioral and emotional disorder marked by aggressive, destructive or deceitful behavior.
The study is published in the journal Drug and Alcohol Dependence.
"Early onset of substance abuse is a significant public health concern," says William Brinkman, MD, a pediatrician at Cincinnati Children's Hospital Medical Center ...
INDIANAPOLIS -- As hospice for nursing home patients grows dramatically, a new study from the Regenstrief Institute and the Indiana University Center for Aging Research compares the characteristics of hospice patients in nursing homes with hospice patients living in the community. The study also provides details on how hospice patients move in and out of these two settings.
Longer lengths of hospice care, rising costs and concerns over possible duplication of services have led to increased scrutiny by policymakers of hospice patients living in nursing homes. Nursing ...
E-cigarettes appear to be less addictive than cigarettes for former smokers and this could help improve understanding of how various nicotine delivery devices lead to dependence, according to researchers.
"We found that e-cigarettes appear to be less addictive than tobacco cigarettes in a large sample of long-term users," said Jonathan Foulds, professor of public health sciences and psychiatry, Penn State College of Medicine.
The popularity of e-cigarettes, which typically deliver nicotine, propylene glycol, glycerin and flavorings through inhaled vapor, has increased ...
PHILADELPHIA -Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries. Further, simeprevir proved to be simpler for patients and had fewer adverse events. The complete study is now available online and is scheduled to publish in January 2015 in The Lancet Infectious Diseases. ...
